CIK 0001175680 · Non-accelerated filer<br>Smaller reporting company
CytoDyn Inc.
Sign in to watch- Ticker
- CYDY
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- May 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 753056237
- Phone
- 360-980-8524
- Business address
- 1111 MAIN STREET, SUITE 660, VANCOUVER, WA, 98660
- Former names
- CYTODYN INC, REXRAY CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-08-06 | Migliarese Antonio Chief Financial Officer | Grant or award · Non-qualified stock option (right to buy) | +1,000,000 | 1,000,000 | ||
| 2021-08-06 | Recknor Chris P Chief Operating Officer | Grant or award | +19,384 | 686,050 | ||
| 2021-08-06 | Recknor Chris P Chief Operating Officer | Grant or award · Non-qualified stock option (right to buy) | +1,450,000 | 1,450,000 | ||
| 2021-04-19 | Naydenov Jordan G Director | Option exercise | +250,000 | $1.35 | $338K | 6,701,323 |
| 2021-04-19 | Naydenov Jordan G Director | Option exercise · Warrant (right to buy) | −250,000 | 0 | ||
| 2021-02-05 | Kelly Scott A. Chairman & CMO | Option exercise | +166,000 | $0.75 | $125K | 782,408 |
| 2021-02-05 | Kelly Scott A. Chairman & CMO | Returned to the company · Warrant (right to buy) | −166,000 | 0 | ||
| 2020-12-22 | Mulholland Michael D. Chief Financial Officer | Option exercise | +161,801 | $0.87 | $141K | 445,882 |
| 2020-12-22 | Mulholland Michael D. Chief Financial Officer | Option exercise | +150,000 | $0.90 | $135K | 595,882 |
| 2020-12-22 | Mulholland Michael D. Chief Financial Officer | Option exercise | +300,000 | $1.09 | $327K | 895,882 |
| 2020-12-22 | Mulholland Michael D. Chief Financial Officer | Option exercise | +100,000 | $1.40 | $140K | 995,882 |
| 2020-12-22 | Mulholland Michael D. Chief Financial Officer | Sale | −245,704 | $5.49 | $1.3M | 750,178 |
| 2020-12-22 | Mulholland Michael D. Chief Financial Officer | Sale | −453,997 | $6.61 | $3.0M | 296,181 |
| 2020-12-22 | Mulholland Michael D. Chief Financial Officer | Sale | −12,100 | $7.00 | $85K | 284,081 |
| 2020-12-22 | Mulholland Michael D. Chief Financial Officer | Option exercise · Non-qualified Stock Option (right to buy) | +161,801 | 0 | ||
| 2020-12-22 | Mulholland Michael D. Chief Financial Officer | Option exercise · Non-qualified Stock Option (right to buy) | +150,000 | 0 | ||
| 2020-12-22 | Mulholland Michael D. Chief Financial Officer | Option exercise · Non-qualified Stock Option (right to buy) | +300,000 | 0 | ||
| 2020-12-22 | Mulholland Michael D. Chief Financial Officer | Option exercise · Non-qualified Stock Option (right to buy) | +100,000 | 0 | ||
| 2020-12-21 | Mulholland Michael D. Chief Financial Officer | Option exercise | +201,598 | $0.57 | $115K | 485,679 |
| 2020-12-21 | Mulholland Michael D. Chief Financial Officer | Option exercise | +300,000 | $0.80 | $240K | 785,679 |
Page 9 of 33 · 652 trades